Axsome Therapeutics, Inc.
AXSM · NASDAQAXSM has an annual revenue baseline of $638.5M, latest revenue marker of $191.2M Q1 2026, annual net income of -$183.2M and cash of $305.1M. The thesis depends on revenue durability, margins, cash conversion and balance-sheet discipline.
Financials and workspace tools are for paid members.
Paid login unlocks company financials, filing timeline, peer comparison, scorecard, and discussion. Valuation remains admin-only while we finalize market-data licensing.